Institutional investors purchased a net $6.3 million shares of THRX during the quarter ended June 2014. This may signal that the smart money is gaining interest in this company as the 84.16% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
FIDELITY MANAGEMENT & RESEARCH C... Bought 3.2 Million shares of Theravance Inc
PERRY CORP. (NEW YORK) Bought 1.5 Million shares of Theravance Inc
BLACKROCK FUND ADVISORS Bought 1.5 Million shares of Theravance Inc